ViroGates A/S, a medical technology company, provides various products to measure soluble urokinase plasminogen activating receptor in blood. More Details
+ 1 more risk
Flawless balance sheet and overvalued.
Share Price & News
How has ViroGates's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: VIRO is more volatile than 75% of Danish stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: VIRO's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Danish stocks.
7 Day Return
DK Medical Equipment
1 Year Return
DK Medical Equipment
Return vs Industry: VIRO exceeded the Danish Medical Equipment industry which returned 19% over the past year.
Return vs Market: VIRO exceeded the Danish Market which returned 23.7% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is ViroGates's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StWe Think ViroGates (CPH:VIRO) Can Afford To Drive Business Growth
4 months ago | Simply Wall StWe're Hopeful That ViroGates (CPH:VIRO) Will Use Its Cash Wisely
8 months ago | Simply Wall StHow Much Of ViroGates A/S (CPH:VIRO) Do Insiders Own?
Is ViroGates undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate VIRO's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate VIRO's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: VIRO is unprofitable, so we can't compare its PE Ratio to the DK Medical Equipment industry average.
PE vs Market: VIRO is unprofitable, so we can't compare its PE Ratio to the Danish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate VIRO's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: VIRO is good value based on its PB Ratio (6.7x) compared to the DK Medical Equipment industry average (10.3x).
How is ViroGates forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ViroGates has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine ViroGates's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- ViroGates competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has ViroGates performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VIRO is currently unprofitable.
Growing Profit Margin: VIRO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VIRO is unprofitable, and losses have increased over the past 5 years at a rate of 29.7% per year.
Accelerating Growth: Unable to compare VIRO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VIRO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-23.9%).
Return on Equity
High ROE: VIRO has a negative Return on Equity (-58.93%), as it is currently unprofitable.
How is ViroGates's financial position?
Financial Position Analysis
Short Term Liabilities: VIRO's short term assets (DKK42.4M) exceed its short term liabilities (DKK7.3M).
Long Term Liabilities: VIRO has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: VIRO is debt free.
Reducing Debt: VIRO had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VIRO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: VIRO has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 29.2% each year.
What is ViroGates's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VIRO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VIRO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VIRO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VIRO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VIRO's dividend in 3 years as they are not forecast to pay a notable one for the Danish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jakob Knudsen (52 yo)
Mr. Jakob Knudsen has been Director at ExpreS2ion Biotech Holding AB (publ) since April 19, 2017. Mr. Knudsen has been the Chief Executive Officer at ViroGates A/S since April 2011. Mr. Knudsen serves as a...
|Chief Executive Officer||9.75yrs||no data||0.16% |
|Co-Founder & Chief Scientific Officer||21yrs||no data||9.86% |
|Chief Financial Officer||1.25yrs||no data||no data|
|Vice President of Accounting||1.25yrs||no data||no data|
|Vice President of Global Sales & Marketing||2.83yrs||no data||0.019% |
Experienced Management: VIRO's management team is considered experienced (2.8 years average tenure).
|Director||4.75yrs||no data||10.44% |
|Independent Director||0.42yr||no data||no data|
|Independent Director||20yrs||no data||0.33% |
|Scientific Advisor||no data||no data||no data|
|Independent Chairman of the Board||5.92yrs||no data||0.11% |
|Scientific Advisor||14yrs||no data||no data|
Experienced Board: VIRO's board of directors are considered experienced (5.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3%.
ViroGates A/S's company bio, employee growth, exchange listings and data sources
- Name: ViroGates A/S
- Ticker: VIRO
- Exchange: CPSE
- Founded: 2000
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: kr.240.459m
- Shares outstanding: 3.12m
- Website: https://www.virogates.com
Number of Employees
- ViroGates A/S
- Blokken 45
- Capital Region of Denmark
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|VIRO||CPSE (OMX Nordic Exchange Copenhagen)||Yes||Share Capital||DK||DKK||Jun 2018|
ViroGates A/S, a medical technology company, provides various products to measure soluble urokinase plasminogen activating receptor in blood. The company develops and markets suPARnostic, a blood test used...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/26 18:06|
|End of Day Share Price||2021/01/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.